Kevin Presley
Family Medicine · Springfield, MONPI 1275720443
Payments from drug & device makers
Across 481 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$905
- Lilly USA, LLC$774
- Novo Nordisk$691
- Takeda Pharmaceuticals U.S.A., Inc.$675
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$456
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,847100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $1,034 |
| AbbVie(2 entities) | 60 | $905 |
| Lilly USA, LLC | 50 | $774 |
| Novo Nordisk | 42 | $691 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $675 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $456 |
| Pfizer | 34 | $376 |
| Otsuka America Pharmaceutical, Inc. | 18 | $332 |
| Biohaven Pharmaceuticals, Inc. | 21 | $231 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $213 |
| Abbott | 9 | $198 |
| Sanofi-aventis U.S. LLC | 12 | $193 |
| Boehringer Ingelheim | 9 | $175 |
| Amgen | 10 | $175 |
| Lundbeck LLC | 11 | $159 |
| Novartis | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 11 | $153 |
| Eisai Inc. | 8 | $140 |
| Bayer | 6 | $87 |
| Merck | 5 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $76 |
| Collegium Pharmaceutical, Inc. | 3 | $73 |
| GSK | 5 | $70 |
| Axsome Therapeutics, Inc. | 2 | $67 |
| Mylan Specialty L.p. | 5 | $67 |
| Exact Sciences | 3 | $50 |
| Ultragenyx Pharmaceutical Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Johnson & Johnson | 2 | $29 |
| Phadia US Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
| Apria Healthcare LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$107
How this compares
$7,847 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $129,970 |
| JardianceEmpagliflozin | 98 | $90,750 |
| MounjaroTirzepatide | 87 | $90,659 |
| EliquisApixaban | 111 | $86,768 |
| TrulicityDulaglutide | 52 | $53,016 |
| Nurtec OdtRimegepant Sulfate | 38 | $50,020 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $34,403 |
| FarxigaDapagliflozin Propanediol | 47 | $32,253 |
| LinzessLinaclotide | 32 | $25,707 |
| RexultiBrexpiprazole | 16 | $24,263 |
| RybelsusSemaglutide | 19 | $22,122 |
| OxycontinOxycodone Hcl | 12 | $21,051 |
| TrintellixVortioxetine Hydrobromide | 19 | $15,986 |
| Xigduo XrDapaglifloz Propaned/Metformin | 24 | $15,936 |
| JanuviaSitagliptin Phosphate | 23 | $13,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $691 | $152,092141 claims |
| Lilly USA, LLCMounjaro, Trulicity | $774 | $143,675139 claims |
| PfizerEliquis, Nurtec Odt | $376 | $136,788149 claims |
| Boehringer IngelheimJardiance | $175 | $90,75098 claims |
| AbbVieLinzess, Ubrelvy, Savella | $905 | $42,71659 claims |
| AstraZenecaFarxiga, Symbicort | $1,034 | $39,70477 claims |
| GSKTrelegy Ellipta | $70 | $34,40330 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $332 | $24,26316 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $675 | $15,98619 claims |
| MerckJanuvia | $80 | $13,96123 claims |
| Johnson & JohnsonXarelto | $29 | $10,15918 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $9,79616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Springfield
- William HowittSpringfield$19.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Stephen AdamsSpringfield$636K
- Cory BethmannSpringfield$621K
- Roger CadySpringfield$175K
- Don BrockmanSpringfield$31K
- James van RiessenSpringfield$25K
- Timothy JenningsMaryland Heights$30.2M
- Rupal TrivediSaint Louis$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.